Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.36 |
| ▸ | CDK2 | P24941 | 5/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890246 | 0.84 | CHRNB2 (0.38) | P2RX7CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL13154196 | 0.84 | HCAR3 (0.38) | P2RX7CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL890146 | 0.83 | EPHX2 (0.40) | P2RX7CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL19364788 | 0.79 | CHRNB2 (0.35) | P2RX7CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL8908938 | 0.79 | KDM4E (0.39) | P2RX7CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL7511795 | 0.73 | CHRNB2 (0.42) | P2RX7ALDH1A1LPAR1HCAR3IRAK4 | |
| SCHEMBL7429834 | 0.73 | CHRNB2 (0.42) | P2RX7ALDH1A1LPAR1HCAR3IRAK4 | |
| SCHEMBL30797267 | 0.73 | HCAR3 (0.43) | P2RX7LPAR1HCAR3IRAK4CHRNB2 | |
| SCHEMBL29416422 | 0.73 | SMN1; SMN2 (0.44) | P2RX7ALDH1A1CCNA2CDK2CCNA1 | |
| SCHEMBL8921088 | 0.72 | MEN1 (0.37) | ALDH1A1MEN1KMT2ACCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013059278-A2 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2012021704-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2011031934-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010096462-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010091413-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | P2RX7 1072/4885ALDH1A1 287/4885MEN1 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.